<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    What does CRDL's zero EPS in Q2 2024 indicate?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/12/2025 05:17pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Cardiol Therapeutics Inc.'s (CRDL) zero EPS in Q2 2024 indicates that the company's earnings for that quarter are expected to be $0. This means that analysts anticipate the company will not earn any profit during that period. A zero EPS can occur due to various reasons such as strategic decisions, market conditions, or operational challenges. It is important to note that a zero EPS does not necessarily indicate a negative outlook for the company, as it can also happen due to planned expenditures or investments.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak){return {layout:"default",data:[{noData:b,currentQuestion:d,textDescription:C,comeFrom:"AInvestShareLink",events:[],answerSource:i}],fetch:{},error:j,state:{sharePreviewModule:{loadJgySuccess:f,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:t,agent_id:a,output_media_info:[],task_id:a,language:a,source:i,cache_builder:a,reply_action:"Answer",execute_mode:u,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"What does CRDL's zero EPS in Q2 2024 indicate?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"What does CRDL's zero EPS in Q2 2024 indicate?\",\"user_id\":\"dp68921105\",\"user_name\":\"\",\"trace_id\":\"f1dc0adb-05a0-4b75-a554-57d5653b9849\",\"session_id\":\"f1dc0adb-05a0-4b75-a554-57d5653b9849\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:t,title:D,summary:E,full_summary:"Get Cardiol Therapeutics alerts: Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Analysts at Roth Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of ($0.09) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS. Several other analysts also recently weighed in on CRDL. Canaccord Genuity Group lifted their target price on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Roth Mkm started coverage on shares of Cardiol Therapeutics in a research note on Wednesday. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research report on Friday, June 14th. Finally, Canaccord Genuity Group raised their target price on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Cardiol Therapeutics currently has an average rating of “Buy” and a consensus price target of $7.60. View Our Latest Analysis on CRDL Cardiol Therapeutics Price Performance NASDAQ CR",url:F,image_url:a,video_url:a,publish_time:G,search_extra_info:{search_burial_info:{id:H,uid:v,ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]}}},simhash:"6aad52db3a2fdb6c",msg_id:v}}],answer_chain_name:L,agent_mode:M,native_answer:a,come_from:a,text_answer:C,trace_id:e,cost:10712,event_names:a,question:d,fallback_type:N,input_type:O,fall_back_reason:{fall_back_type:N,risk_detail:{matched_words:[]}},session_id:e,first_return_cost:2835,cache_type:a,question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:P,remote_svc:i,slots:[],answer_type:u,user_id:o,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:o,question:d,source:i,raw_question:d,version:"3.4.1",action_name:w,nlu:{entity:[{type:Q,value:"CRDL.O",market:R}]},deep_research:b,deep_thinking:b,agent_mode:M},extra:{}},{answer_path:p,section:{id:q,info_texts:["Thinking"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"begin"},logs:[],extra:{is_deep_research:b,deep_thinking:b}},{answer_path:p,section:{id:q,info_texts:["Searching Web: Why Does CRDL's EPS Zero in Q2 2024"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"thinking"},logs:[],extra:{action:"Searching Web",action_input:"Why Does CRDL's EPS Zero in Q2 2024",thought:"The user wants to know what CRDL's zero EPS in Q2 2024 indicate. I should focus on the zero EPS in Q2 2024的原因. I will use Search for the reason of CRDL's zero EPS in Q2 2024."}},{answer_path:g,section:{id:S,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:g,section:{id:S,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:p,section:{id:q,info_texts:["Generating Answer"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"ongoing"},logs:[],extra:{}},{answer_path:g,section:{id:y,info_texts:[],show_type:z,voice_txt:"Card",text_answer:T,rich_text:T,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:g,section:{id:2000,info_texts:[],show_type:z,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:F,image_url:a,video_url:a,title:D,summary:E,index:t,publish_time:G,search_id:H,search_uid:v,search_ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]},jump_type:"normal"}],is_last:c},logs:[],extra:{}},{answer_path:g,section:{id:y,info_texts:[],show_type:z,voice_txt:". This",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:g,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"CRDL",market_id:R,name:V,domain:Q},pos:f,section_id:y,txt:V,jump_type:"pos_fenshi"}],is_last:c},logs:[],extra:{}},{answer_path:p,section:{id:q,info_texts:["Completed"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:k,query_text:k,trace_info:{item_id:"f751b54d9308b2144d4736ef4c8c7fc2",item_type:h,item_name:k,rec_info:W}},{display_text:l,query_text:l,trace_info:{item_id:"83a46585fd4f54b8246f7a2490478bff",item_type:h,item_name:l,rec_info:X}},{display_text:m,query_text:m,trace_info:{item_id:"db32ab79125dec29ee88adc488c3998d",item_type:h,item_name:m,rec_info:Y}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:b,txt_style:f,type:"1",display2:b,url:a}},request_config:[{source_type:Z,related_name:_}],puuid:A,tag:a,category:"custom",uuid:$}],global:{urp_static_data:[{name:_,value:{status_code:f,columns:[{type:n,index_name:aa,key:aa},{type:n,index_name:ab,key:ab},{type:n,index_name:ac,key:ac},{type:n,index_name:ad,key:ad},{type:n,index_name:ae,key:ae}],datas:[{send_text:k,item_type:h,rec_info:W,display_text:k,rec_reason:a},{send_text:l,item_type:h,rec_info:X,display_text:l,rec_reason:a},{send_text:m,item_type:h,rec_info:Y,display_text:m,rec_reason:a}],dataSize:Z,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:b,visible:c,childLimit:9999,label:af,type:"thslc\u002Fthslc-common-container",leaf:b,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:c,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:s,"min-height":"100%",position:ag,height:s},isMaterial:b,id:af,needTheme:b,hasEditor:b,packed:b,events:[],child:[{readmeUrl:"https:",stack:b,visible:c,customStyle:a,childLimit:f,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:c,version:"1.12.0",animate:[],url:B,componentUuid:$,script:[{name:ah,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:c,renderType:"blue"},path:B,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:B},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:s,position:ag,height:s},isMaterial:c,_id:19,id:ah,hasEditor:c,packed:b,events:[],isSetDefaultValue:c}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ai,voice_txt:a,tracking_info:{},uuid:A},order:{is_auto:b,render_for:ai,chart_type:"command",puuid:A}},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{action_name:w,with_paid_index:b,no_refresh_answer:b,answer_source:{agent_id:a,agent_name:a,execute_mode:u,answer_chain_name:L},is_deep_research:b,deep_thinking:b,create_time:1744449445800},is_last:c}],questionItem:{data:{qStr:d,encodeFlag:b,imageData:j,docsData:[],quoteData:j},tplType:"question"},events:aj,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:aj,client_ip:a,question:d,user_id:o,user_name:a,trace_id:e,session_id:e,source:i,input_type:O}}],userId:o,userName:a,startTime:P,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:j,endSignal:b,theme:"white",showTracePopup:b,traceListData:[],chatTraceTargetIndex:f,traceTableData:j,showMask:b}},serverRendered:c,routePath:"\u002Faime\u002Fshare\u002Fwhat-does-crdls-zero-eps-in-q2-2024-indicate-51b719\u002F",config:{_app:{basePath:ak,assetsPath:ak,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",false,true,"What does CRDL's zero EPS in Q2 2024 indicate?","f1dc0adb-05a0-4b75-a554-57d5653b9849",0,"other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,"💼 What is CRDL's current price-to-earnings ratio?","📊 How does CRDL's Q2 2024 EPS compare to analyst expectations?","🚦 What is the short-term technical outlook for CRDL's stock?","STR","dp68921105","progress\u002Fsearching_for",1000,"searching_for","auto",1,"agent","d25edcbdaebf8a6d","review stocks","signal",2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Cardiol Therapeutics Inc.'s (CRDL) zero EPS in Q2 2024 indicates that the company's earnings for that quarter are expected to be $0. This means that analysts anticipate the company will not earn any profit during that period. A zero EPS can occur due to various reasons such as strategic decisions, market conditions, or operational challenges. It is important to note that a zero EPS does not necessarily indicate a negative outlook for the company, as it can also happen due to planned expenditures or investments.","Q2 2024 Earnings Estimate for Cardiol Therapeutics Inc. (NASDAQ:CRDL) Issued By Roth Capital","Get Cardiol Therapeutics alerts: Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Analysts at Roth Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes ...","https:\u002F\u002Fwww.americanbankingnews.com\u002F2024\u002F06\u002F28\u002Fq2-2024-earnings-estimate-for-cardiol-therapeutics-inc-nasdaqcrdl-issued-by-roth-capital.html","2024-06-28","d25edcbdaebf8a6d_0","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744449435088,"stock","186",999,"Cardiol Therapeutics Inc.'s (CRDL) zero EPS in Q2 2024 indicates that the company's earnings for that quarter are expected to be $0[^1]",". This means that analysts anticipate the company will not earn any profit during that period. A zero EPS can occur due to various reasons such as strategic decisions, market conditions, or operational challenges. It is important to note that a zero EPS does not necessarily indicate a negative outlook for the company, as it can also happen due to planned expenditures or investments.","Cardiol Therapeutics","2+679_496_21_554+0+0+f1dc0adb-05a0-4b75-a554-57d5653b9849+f751b54d9308b2144d4736ef4c8c7fc2+llm_generated+aimeTagAnalysis+0+0.11411267518997192+1","2+679_496_21_554+0+0+f1dc0adb-05a0-4b75-a554-57d5653b9849+83a46585fd4f54b8246f7a2490478bff+llm_generated+aimeTagAnalysis+0+0.08550074696540833+2","2+679_496_21_554+0+0+f1dc0adb-05a0-4b75-a554-57d5653b9849+db32ab79125dec29ee88adc488c3998d+llm_generated+aimeTagAnalysis+0+0.07448320835828781+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>